Sabine Reiterer-Cerny

Vienna, 1090, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications

Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Phenotyping and Target Expression Profiling of CD34+/CD38- and CD34+/CD38+ Stem- and Progenitor cells in Acute Lymphoblastic Leukemia.

Journal: Neoplasia (New York, N.Y.)
Published: February 08, 2018

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.

The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells.

Journal: Oncotarget
Published: December 21, 2016

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Journal: The Journal of clinical investigation
Published: September 23, 2016

The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

Journal: Veterinary and comparative oncology
Published: March 31, 2016

IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.

IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.

Journal: Veterinary and comparative oncology
Published: February 25, 2016

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.

Journal: Blood
Published: November 12, 2015

Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.

Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia.

Journal: Leukemia
Published: October 23, 2015

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm.

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm.

Journal: Wiener klinische Wochenschrift
Published: October 02, 2015

Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.

Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56bright NK cell subpopulations in patients with acute myeloid leukemia and supports their activation.

Journal: Oncotarget
Published: August 25, 2015

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Identification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 03, 2015

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Journal: Blood
Published: March 31, 2015

Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.

Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q.

Journal: Leukemia
Published: March 21, 2015
Showing 1-12 of 39

Last Updated: 09/26/2026